Vascular Impact of Omega-3 in Metabolic Syndrome (CARDIOMEGA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University Hospital, Rouen
ClinicalTrials.gov Identifier:
NCT01566188
First received: December 8, 2011
Last updated: September 1, 2014
Last verified: September 2014
  Purpose

The overall aims of the present project are to investigate the impact of a nutritional approach based on omega-3 from vegetal origin on vascular function in hypertension associated with metabolic syndrome.


Condition Intervention
Essential Hypertension
Metabolic Syndrome
Dietary Supplement: omega-3 from vegetal origin
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: Cardiovascular Impact of Omega-3 Dietary Supplement From Vegetal Origin in Hypertension Associated With Metabolic Syndrome

Resource links provided by NLM:


Further study details as provided by University Hospital, Rouen:

Primary Outcome Measures:
  • Brachial artery flow-mediated dilatation [ Time Frame: 6 months after omega-3 supplementation ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Aortic stiffness [ Time Frame: 6 months after omega-3 supplementation ] [ Designated as safety issue: No ]
    carotid-to-femoral pulse wave velocity


Enrollment: 95
Study Start Date: January 2011
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: omega-3 from vegetal origin Dietary Supplement: omega-3 from vegetal origin
6 months of supplementation with omega-3 from vegetal origin
Other Name: Cyclodextrin/Camelin oil
Placebo Comparator: Placebo Dietary Supplement: Placebo
6 months of supplementation with placebo
Other Name: Cyclodextrin/Starch

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female and male patients with treated essential hypertension (blood pressure values<140/90 mmHg under antihypertensive treatment).
  • Presence of at least two of the following criteria of the metabolic syndrome: abdominal girth >102 cm in men or >88 cm in women, HDL-C<0.4 g/L in men or <0.5 g/L in women, fasting triglyceride >1.5 g/L (or specific treatment for these lipid abnormalities), fasting glucose >1.10 g/L.

Exclusion Criteria:

  • Secondary hypertension, myocardial infarction, coronary artery disease, cerebrovascular disease, stroke or transient ischemia, cardiac failure, diabetes (or fasting glucose>1.26 g/L) or renal failure (MDRD < 50 ml/min)
  • Severe hypercholesterolemia (total cholesterol > 2.5 g/l), alcohol or drug abuse, toxicomania, or clinically significant abnormalities in other current biological parameters.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01566188

Locations
France
Mahes Hospital
Fleury-Mérogis, France, 91700
George Pompidou European Hospital
Paris, France, 75000
Rouen University Hospital
Rouen, France, 76031
Rangueil University Hospital
Toulouse, France, 31059
Sponsors and Collaborators
University Hospital, Rouen
Investigators
Principal Investigator: Robinson Joannides, MD, PhD Rouen University Hospital
  More Information

No publications provided

Responsible Party: University Hospital, Rouen
ClinicalTrials.gov Identifier: NCT01566188     History of Changes
Other Study ID Numbers: 2010/010 HP
Study First Received: December 8, 2011
Last Updated: September 1, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Hypertension
Metabolic Syndrome X
Syndrome
Cardiovascular Diseases
Disease
Glucose Metabolism Disorders
Hyperinsulinism
Insulin Resistance
Metabolic Diseases
Pathologic Processes
Vascular Diseases

ClinicalTrials.gov processed this record on October 21, 2014